title: Is there a difference between various presentations of valproate for cognitive outcome after in utero exposure?
authors.affiliation: Epilepsy Unit, Gui de Chauliac Hospital, Montpellier, France. p_gelisse@hotmail.com.|Department of Neurobiology, Research Unit "Movement Disorders" (URMA), Institute of Functional Genomics, CNRS UMR5203 - INSERM U661 - UM1, Montpellier, France. p_gelisse@hotmail.com.
authors.forename: Philippe
authors.initials: P
authors.lastname: Gelisse
authors.affiliation: Sant-Paul Center-Henri Gastaut, Marseille, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Genton
authors.affiliation: Epilepsy Unit, Gui de Chauliac Hospital, Montpellier, France.|Department of Neurobiology, Research Unit "Movement Disorders" (URMA), Institute of Functional Genomics, CNRS UMR5203 - INSERM U661 - UM1, Montpellier, France.
authors.forename: Arielle
authors.initials: A
authors.lastname: Crespel
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced* / Q000175:diagnosis*; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000927:Anticonvulsants; D014635:Valproic Acid